Imagine cells needing a place to grow, like plants needing soil. Instead of flat plates, this technology creates tiny, fluffy 3D scaffolds that act like high-density sponges. These sponges provide way more room for cells to attach and grow, making the production of complex medicines much faster and more efficient.
Next-generation therapies face low yields and high costs when scaling from R&D to clinical manufacturing. Current microcarriers lack the surface area and 3D environment needed for efficient cell growth.
A platform of customizable nanofiber microcarriers (Cellevat3d) and a validated production line for biological drug manufacturing.
If you are a gene therapy producer dealing with low yields and high costs — this project developed cellulose-based nanofiber microcarriers that provide a 60 times larger growth area. This allows for more efficient AAV vector production to accelerate market access.
If you are a biotech firm dealing with difficulties scaling processes from R&D to clinical manufacturing — this project developed the Cellevat3d platform. It replicates the human body's 3D environment to ensure high-quality stem cell growth at scale.
If you are a vaccine manufacturer dealing with inefficient upstream processing — this project developed customizable nanofiber scaffolds. These tools improve production economy and reduce the overall cost of biological drug manufacturing.
The platform enhances production economy and reduces costs by tackling critical issues in upstream processing and increasing yields.
Yes, the project specifically focused on production scale-up and validated performance with partners like the Testa Centre for large-scale gene therapy production.
The technology is based on a patent-pending nanofiber scaffold production technology (PCT/EP2020/081958).
The commercial rollout was achieved ahead of schedule in November 2024.
Based on available project data, the microcarriers are designed for use in bioreactors and were benchmarked for process economy by the Fraunhofer Institute.
The project was led by a single Swedish SME, Cellevate AB, but expanded its reach significantly. While the formal consortium remained small, the company engaged 31 external partners for validation, including prestigious institutions like the Max Planck Institute and Karolinska Institutet, as well as industrial giants like Charles River Laboratories, ensuring strong market validation.
Contact Cellevate AB in Sweden regarding the Cellevat3d platform.
Contact us to connect with Cellevate AB for licensing or procurement of SBMP-microcarriers.
